X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com/news-release/2024/04/30/2872207/20739/en/Ultragenyx-Announces-Completion-of-Enrollment-in-Phase-3-Orbit-and-Cosmic-Studies-Evaluating-Setrusumab-UX143-for-the-Treatment-of-Osteogenesis-Imperfecta-OI.html
https://www.globenewswire.com/news-release/2024/03/27/2853597/0/en/Mereo-BioPharma-Reports-Full-Year-2023-Financial-Results-and-Provides-Corporate-Update.html
https://www.globenewswire.com//news-release/2023/10/09/2756624/20739/en/Ultragenyx-to-Present-Setrusumab-UX143-Update-at-ASBMR-2023-Including-New-Data-from-Phase-2-3-Orbit-Study-in-Osteogenesis-Imperfecta-OI.html
https://www.globenewswire.com/news-release/2023/07/06/2700255/20739/en/Ultragenyx-Announces-First-Patients-Dosed-in-Phase-3-Program-Evaluating-Setrusumab-UX143-for-the-Treatment-of-Osteogenesis-Imperfecta-OI.html
https://www.globenewswire.com/news-release/2023/06/05/2682355/20739/en/Ultragenyx-and-Mereo-BioPharma-Announce-Positive-Data-from-the-Ongoing-Phase-2-3-Orbit-Study-of-Setrusumab-UX143-in-Osteogenesis-Imperfecta-OI.html
https://www.globenewswire.com/news-release/2022/09/10/2513537/20739/en/Ultragenyx-and-Mereo-BioPharma-to-Present-Setrusumab-Data-Update-at-ASBMR.html
https://www.globenewswire.com/news-release/2022/04/20/2425399/20739/en/Ultragenyx-Announces-First-Patient-Dosed-in-Pivotal-Phase-2-3-Clinical-Study-of-Setrusumab-UX143-for-the-Treatment-of-Osteogenesis-Imperfecta.html
https://www.globenewswire.com/news-release/2020/12/17/2147399/0/en/Ultragenyx-and-Mereo-BioPharma-Announce-Collaboration-and-License-Agreement-for-Setrusumab-in-Osteogenesis-Imperfecta.html#:~:text=Under%20the%20terms%20of%20the,where%20Mereo%20retains%20commercial%20rights.
https://www.globenewswire.com/news-release/2020/12/17/2147399/0/en/Ultragenyx-and-Mereo-BioPharma-Announce-Collaboration-and-License-Agreement-for-Setrusumab-in-Osteogenesis-Imperfecta.html#:~:text=Under%20the%20terms%20of%20the,where%20Mereo%20retains%20commercial%20rights.
https://www.globenewswire.com/news-release/2020/09/24/2098559/0/en/Mereo-BioPharma-Receives-FDA-Rare-Pediatric-Disease-Designation-for-Setrusumab-for-the-Treatment-of-Osteogenesis-Imperfecta.html
http://www.pmlive.com/pharma_news/celgene_says_no_to_mereos_cancer_drug_etigilimab_1291381
http://www.pmlive.com/pharma_news/mereos_shareholders_back_oncomed_takeover_1284951
Market Place
Share 
